Advantages of blood pool contrast agents in MR angiography: a pictorial review.

Gadofosveset trisodium (Ablavar®, formerly Vasovist®) is the first intravascular contrast agent approved for clinical use in peripheral vascular disease. The purpose of this review is to illustrate the clinical uses of gadofosveset-enhanced magnetic resonance angiography in patients referred for assessment of arteriovenous disease. Superior T1 shortening enables first pass renal and peripheral arteriography of quality comparable with larger doses of extracellular agents. In applications such as thoracic outlet syndrome, there may be other advantages such as superior venous imaging and need for only one injection. Steady-state delayed imaging provides high resolution mapping of both arterial and venous systems and imaging of multiple territories. A combination of dynamic and delayed steady-state imaging can provide detailed anatomy and flow characteristics of vascular malformations and mapping for percutaneous sclerotherapy at one investigation. The ability to image in the steady state can provide minimally invasive imaging of thrombo-occlusive disease of central veins.